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Chronic Human Herpes Virus 8 Infection Successfully
Treated with Valganciclovir
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Background: A 57 year old Italian female with a 3 year history of
constituitional symptoms with non-HIV Kaposi sarcoma was re-
ferred to the immunology clinic. She was previously diagnosed with
chronic human herpes virus 8 (HHV8) infection with positive HHV8
polymerase chain reaction in serum.
Objective: Is valganciclovir effective in treating chronic human
herpes virus 8 infection without Multicentric Castleman’s Disease
(MCD)?
Results: She was started on valganciclovir, resulting in remission of
her symptoms, improvement in inflammatory markers and clearing
of detectable HHV8 viraemia
Conclusion: Valganciclovir is effective in treating symptomatic
HHV8 infections without MCD.
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sarcoma
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INTRODUCTION
A 57-year-old Italian female with a 3-year history of dailyrecurrent fever, severe fatigue, arthralgia, and cutaneous
Kaposi sarcoma (KS) was referred to the immunology clinic for
the management of human herpes virus 8 (HHV8) infection.
BACKGROUND HISTORY
After a partial gastrectomy for leiomyoma in July 2004,
our patient noted daily recurrent fevers up to 38.5°C. This
was associated with profound lethargy and severe functional
impairment in performing daily living activities. She reported
generalized polyarthropathy; however, on clinical examina-
tion, there was no evidence of active arthritis. There was no
history of weight loss and on examination there was no
palpable lymphadenopathy. Extensive investigations were
performed including gallium scan, bone scan, CT scan of
sinuses, chest, abdomen, and pelvis, and multiple serologies
for immunologic and infectious diseases with no definitive
diagnosis. She was negative for human immunodeficiency
virus (HIV), hepatitis B, and hepatitis C. Autoimmune
screens including anti-nuclear antibody, extractable nuclear
antigen, and double-stranded DNA, rheumatoid factor, and
anti-cyclic citrullinated peptide, anti-neutrophil cytoplasm,
and anti-thyroid antibodies were negative. Serum electro-
phoresis and immunoelectrophoresis showed no paraprotein-
aemia. Familial Mediterranean fever antibodies were nega-
tive. Immunoglobulins and complement levels were normal.
Lymphocyte subsets were normal. Endocrine hormone levels
were within normal range. Mantoux testing was negative.
Two years after the onset of symptoms, she developed
small KS lesions on her fingers, which were biopsy-proven
and biopsy-positive for HHV8. Subsequently, our patient had
blood samples for quantitative HHV8 to Italy. This confirmed
the presence of 80 HHV8 genome equivalents per milliliter of
plasma and 2206 HHV8 genome equivalents per 106 periph-
eral blood mononuclear cells, using calibrated quantitative
real-time polymerase chain reaction (PCR).1 Given the blood
positivity for HHV8, no oral mucosal or salivary samples
were sent for PCR.
In late 2006, 10 cycles of fortnightly cidofovir were
commenced. Her fever and constitutional symptoms im-
proved; however, she complained of nausea. Three months
after completing cidofovir treatment, her symptoms relapsed
and she was referred to the immunology clinic for further
management.
On referral to the immunology clinic, repeat blood tests
revealed mildly elevated C-reactive protein and erythrocyte
sedimentation rate levels and detectable positive HHV8 se-
rology on PCR. A therapeutic trial of acyclovir 200 mg 3
times a day was given with no improvement. Given the
significant toxicities associated with cidofovir and foscarnet,
alternative therapy was sought. A trial of valganciclovir 900
mg daily was prescribed with symptomatic improvement,
reversion to undetectable HHV8 PCR in plasma, and fall in
inflammatory markers, and her KS lesions decreased in size
from more than 1cm to a few millimeters in size. She was
treated with a trial period of 3 months on valganciclovir and
then ceased, with a relapse in her fevers and arthralgias and
increase in number of KS lesions including those on the
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fingers and eyelids. She has recommenced valganciclovir
treatment and is receiving another 6 months of therapy. A
repeat plasma sample has been tested in our National Infec-
tious Diseases Reference Laboratory while the patient is
receiving therapy to monitor response. This is qualitative
only using the TaqMan Rapid Testing Probe Assay and it has
been negative for HHV8. Clinically, our patient’s lesions on
her eyelids and fingers have resolved.
Medical history includes obesity, obstructive sleep ap-
nea, hypertension, and multiple surgeries. Regular medica-
tions were metoprolol and irbesartan.
DISCUSSION
Human herpes virus 8 (HHV8) is a member of the
gammaherpesvirus subfamily, which also includes Epstein-
Barr virus. It is known to cause primary effusion lymphoma,
KS, and multicentric Castleman disease (MCD). Chronic
HHV8 infection presenting with recurrent fever and consti-
tutional symptoms in immunocompetent patients is rarely
reported in the literature. Isolated KS classically is not asso-
ciated with recurrent fevers or constitutional symptoms. In
MCD, patients may present constitutional symptoms but the
absence of lymphadenopathy in this patient makes this diag-
nosis unlikely. Acute primary HHV8 infections may present
with transient, nonspecific symptoms including lymphade-
nopathy, diarrhea, and exanthem, which do not persist for
years as in our patient.2
In 2005, Dagna et al described a case report of a woman
who was HIV-negative with a relapsing inflammatory syn-
drome characterized by fever, lymphadenopathy, splenomeg-
aly, edema, arthrosynovitis, and erythematous rash because
of recurrent episodes of HHV8 re-activation.3 This patient
had 4 recurrences that correlated with the rise in HHV8 viral
load. Each relapse was treated with either daunorubicin,
foscarnet, or cidofovir, which led to suppression of HHV8
viraemia, disappearance of KS, and clinical improvement.3
In contrast to Dagna et al’s case report, our patient had
a 3-year history of fever, debilitating fatigue, arthralgia, and
KS lesions. Lymphadenopathy, splenomegaly, edema, and
rash were absent. Whether our patient had a separate disease
entity or symptoms due to chronic HHV8 viraemia along the
spectrum of MCD and KS is a point of discussion, as
illustrated by the correspondence for the case reported by
Dagna et al.4 Whereas it may be argued that she had a “mild”
disease on a spectrum of the HHV8 associated disease be-
cause of the absence of other clinical features, the severe
debilitating effect of the symptoms on her quality of life must
not be underestimated.
Therapeutic management was a challenge in our pa-
tient. Initially, she demonstrated a good response to cidofovir.
As an ongoing long-term therapeutic option, there were
concerns regarding toxicity and ease of administration. Val-
ganciclovir, administered orally, was chosen as an alterna-
tive, on the basis of the literature reporting successful reduc-
tion in MCD symptoms and HHV8 viraemia.5 A recent
randomized control trial with valganciclovir 900 mg daily in
both HIV and non-HIV patients with evidence of HHV8
shedding from their saliva resulted in a significant reduction
in HHV8 replication.5 This supports the demonstrated re-
sponse in our patient. The resolution of fever and symptom-
atic improvement with valganciclovir correlated with the
suppression of HHV8. The optimal duration of treatment and
further management remain unclear at this point. On the basis
of the randomized control trial, there was rebound shedding
of HHV8 upon cessation of valganciclovir.6
CONCLUSION
We are unaware of other reports of valganciclovir
treatment for symptomatic HHV8 infection without MCD,
and optimal further management remains to be elucidated.
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